Harvard School of Dental Medicine

Vesica Health Appoints Distinguished Urologic Oncologist Dr. William T. Lowrance to Chief Medical Officer

Retrieved on: 
Tuesday, October 31, 2023
Education minister, Harvard School of Dental Medicine, Survival, Huntsman Cancer Institute, Lee University, Hematuria, MPH, American Urological Association, Public health, Master of Business Administration, Hope, Memorial Sloan Kettering Cancer Center, Medical degree, Prostate cancer, Medical University of South Carolina, Bladder cancer, Bon, MBA, Health, Vesica, Memorial, Disease, Risk, Business administration, Business, University, Public, David Eccles School of Business, Medical school, HEALTH, Lowrance Electronics, Liquid biopsy, Patient, Diagnosis, Associate, Vanderbilt University Medical Center, Harvard T.H. Chan School of Public Health, Pharmaceutical industry, Nursing, Urology, MD, Chemistry

Dr. Lowrance brings more than 20 years of clinical experience, as a professor of urology and a practicing urologic oncologist, treating patients and conducting clinical trials.

Key Points: 
  • Dr. Lowrance brings more than 20 years of clinical experience, as a professor of urology and a practicing urologic oncologist, treating patients and conducting clinical trials.
  • "I have devoted my career to researching and treating urologic cancers, striving to improve patient care and ultimately, survival," said Dr. William T. Lowrance, Chief Medical Officer of Vesica Health.
  • Dr. Lowrance is an attending urologic oncologist at Bon Secours Mercy Health, specializing in the treatment of urologic malignancies, with a focus on bladder cancer.
  • While serving as the Chief Medical Officer of Vesica Health, Dr. Lowrance will continue his medical practice at Bon Secours Mercy Health.

Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer

Retrieved on: 
Friday, September 29, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Harvard School of Dental Medicine, Therapy, Cancer, Breast, PI3K, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Public health, Enzalutamide, Patient, Yale University, Phosphine, Albert Einstein College of Medicine, Ovarian cancer, Publius Cornelius Arvina, BLA, Pharmaceutical industry, EU, Gemtuzumab ozogamicin, Pfizer

Faeth Therapeutics , a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer.

Key Points: 
  • Faeth Therapeutics , a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer.
  • Debbie comes to Faeth with years of experience in clinical development and medical affairs, which we look to leverage as we continue the clinical development of our lead assets,” said Anand Parikh, J.D., Chief Executive Officer of Faeth Therapeutics.
  • We aim to empower patients to participate in their care with a science-based, precision approach to nutrition that will enhance their anti-tumor armamentarium,” said Debbie Chirnomas, M.D., M.P.H., Chief Medical Officer of Faeth Therapeutics.
  • “Faeth is a special company with a pioneering mindset based on outstanding science and is uniquely positioned to bring a radically new approach to cancer therapeutics for at-need patients.”

Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Wednesday, July 19, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Merit Cudkowicz, International, Harvard–MIT Program in Health Sciences and Technology, Life, Outline of health sciences, Clinical trial, American Academy, Boston, COYA, Forbes Norris, Harvard Medical School, National Institute of Neurological Disorders and Stroke, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, DSM-IV codes, Massachusetts Institute of Technology, Public health, Beth Israel Hospital, Patient, Coya, Chemical engineering, Master of Science, Hospital, American Academy of Neurology, Massachusetts General Hospital, Therapy, ALS, Harvard School of Dental Medicine, Commerce, Pharmaceutical industry, MD

Dr. Cudkowicz is a world-renowned neurologist who has dedicated her career to improving the life of patients with ALS and other serious neurological conditions.

Key Points: 
  • Dr. Cudkowicz is a world-renowned neurologist who has dedicated her career to improving the life of patients with ALS and other serious neurological conditions.
  • Dr. Cudkowicz brings decades of experience supporting the development of new therapies for ALS.
  • Dr. Cudkowicz has launched the first platform trial initiative in ALS, the HEALEY ALS Platform Trial, a program that helps accelerate therapy development in ALS.
  • Merit Cudkowicz commented: "I am happy to join Coya as a clinical advisor as they move COYA 302 into a well powered and designed clinical trial.

Boston Scientific Elects Dr. Jessica L. Mega and Susan E. Morano to Board of Directors

Retrieved on: 
Tuesday, June 27, 2023
Business development, Stanford University, Boston Scientific, BSX, Columbia Business School, Harvard T.H. Chan School of Public Health, Danaher Corporation, Harvard Medical School, Yale School of Medicine, Mega, Villanova University, Public health, Brigham, B.A, Hospital, Johnson & Johnson, Alphabet Inc., Health, Brigham and Women's Hospital, NYSE, Harvard School of Dental Medicine, Management

MARLBOROUGH, Mass., June 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each effective immediately.

Key Points: 
  • MARLBOROUGH, Mass., June 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each effective immediately.
  • Prior to joining Verily, Dr. Mega served as a cardiologist at Brigham & Women's Hospital from 2008 to 2015.
  • "We are pleased to expand our board of directors with two highly qualified executives from different sectors of the healthcare industry," said Mike Mahoney, chief executive and chairman of the board, Boston Scientific.
  • "Jessica and Susan are accomplished leaders passionate about advancing patient care and experienced in bringing innovative technologies to market, and we look forward to their contributions as board members as Boston Scientific continues to grow and meet our stakeholder commitments."

ADEA Announces 2023-24 Fellows of Its Inaugural Council of Deans Fellowship

Retrieved on: 
Wednesday, June 21, 2023
Health, Other Education, University, Dental, Education, Archives of Oral Biology, Experimental pathology, DRS, CWRU, Maryland School, Chemistry, Fellows, Research, Postgraduate education, CODA, Al-Ghad International Health Sciences Colleges, Prosthodontics, Exhibition, M.A, Indiana University School of Dentistry, Harvard School of Dental Medicine, Dean (education), Oral medicine, Pathology, Case Western Reserve University School of Medicine, Oral and maxillofacial pathology, Sacroiliac joint, University of Siena, ADEA, Western University, American Academy, Association of Christian Universities and Colleges in Asia, Otorhinolaryngology, Diplom, University of Maryland School of Dentistry, Dentistry, New York University, Orofacial pain, Medicine

ADEA is pleased to announce the inaugural class of the ADEA Council of Deans Fellowship (ADEA CDF), a new leadership development program that launched in May.

Key Points: 
  • ADEA is pleased to announce the inaugural class of the ADEA Council of Deans Fellowship (ADEA CDF), a new leadership development program that launched in May.
  • The ADEA CDF is a year-long, part-time fellowship aimed at creating a diverse pipeline of future leaders who will assume roles as dental school deans and other senior university leadership positions.
  • The ADEA CDF will increase the number of qualified candidates for deanships and equip them with the skills and experiences to help them succeed.
  • The ADEA CDF Program Director is Dean Emeritus Steven Friedrichsen, D.D.S., of Western University of Health Sciences College of Dental Medicine.

PM PEDIATRIC CARE ANNOUNCES $50M INVESTMENT FROM SCOPIA CAPITAL AND JEFFERSON RIVER CAPITAL

Retrieved on: 
Tuesday, June 20, 2023
Health policy, Chairperson, OMICS Publishing Group, Internal medicine, Aetna, CVS, Health, Multimedia, Harvard T.H. Chan School of Public Health, Public health, Patient, Foulkes, Growth, CVS Health, Harvard School of Dental Medicine, Nursing

LONG ISLAND, N.Y., June 20, 2023 /PRNewswire/ -- PM Pediatric Care, a nationally recognized leader in the delivery of pediatric care, announces $50M in Series E equity funding led by Scopia Capital, including Jefferson River Capital.

Key Points: 
  • LONG ISLAND, N.Y., June 20, 2023 /PRNewswire/ -- PM Pediatric Care, a nationally recognized leader in the delivery of pediatric care, announces $50M in Series E equity funding led by Scopia Capital, including Jefferson River Capital.
  • The company will also enhance its patient-centered infrastructure and explore additional pediatric service lines, including primary care, as it seeks to become a key component of value-based models of pediatric health care.
  • PM Pediatric Care has treated over 6.5 million patients in 78 urgent care locations across the U.S., as well as thousands of mental and behavioral health patients.
  • "We have never been more confident in the future of PM Pediatric Care," said Steve Katz, Co-Founder & Co-CEO of PM Pediatric Care.

Work Health Solutions Names Dr. Peter Lee Chief Executive Officer

Retrieved on: 
Wednesday, June 14, 2023
Managed Care, Health, Telemedicine, Virtual Medicine, Other Health, University, General Electric, Intuition, American College of Occupational and Environmental Medicine, Boston Medical Center, Chapel Hill, Employment, Global health, Multimedia, Preventive healthcare, University of North Carolina at Pembroke, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Occupational Safety and Health Act 1994, Public health, Medical director, MD, Robert Larner College of Medicine, Global Medical Aid, American College, Harvard School of Dental Medicine, Environmental medicine, Management, Amazon

Work Health Solutions, providers of concierge-style occupational medicine for large-scale employers nationwide, announces the appointment of Peter Lee, MD as Chief Executive Officer.

Key Points: 
  • Work Health Solutions, providers of concierge-style occupational medicine for large-scale employers nationwide, announces the appointment of Peter Lee, MD as Chief Executive Officer.
  • Most recently, Dr. Lee served as Global Medical Director for Amazon where he led clinical operations and industrial hygiene, directed occupational health and wellness, developed worldwide responsive health policies, and drove advancements in health technology, global health security and benefits design.
  • View the full release here: https://www.businesswire.com/news/home/20230614816100/en/
    Peter Lee, MD - Amazon’s Former Global Medical Director, now Chief Executive Officer of Work Health Solutions, providers of concierge-style occupational medicine for large-scale employers nationwide.
  • (Photo: Business Wire)
    “At Amazon, we enlisted Work Health Solutions as a strategic partner, and they exceeded every expectation with their unique approach and exceptional customer service.

THE HOWARD HUGHES CORPORATION® ANNOUNCES APPOINTMENT OF DAVID EUN TO BOARD OF DIRECTORS

Retrieved on: 
Thursday, June 8, 2023
Partnership, Samsung Electronics, Content partnership, Howard Hughes, Business, HHC, Samsung, Harvard College, Harvard Law School, Advisory board, Applied science, Entrepreneurship, Howard Hughes Corporation, NYSE, Harvard School of Dental Medicine, Management, Engineering

HOUSTON, June 8, 2023 /PRNewswire/ -- The Howard Hughes Corporation® (NYSE: HHC) announced today the appointment of David Eun to the company's Board of Directors.

Key Points: 
  • HOUSTON, June 8, 2023 /PRNewswire/ -- The Howard Hughes Corporation® (NYSE: HHC) announced today the appointment of David Eun to the company's Board of Directors.
  • "David will be a superb director, bringing invaluable technological expertise to the company," said Bill Ackman, Chairman of the Board of The Howard Hughes Corporation.
  • "We are delighted to welcome him to the HHC board."
  • Mr. Eun is a graduate of Harvard College and Harvard Law School, where he has served as an Advisory Board member for the Harvard School of Engineering and Applied Sciences.

TriNetX Announces the Appointment of Dr. K. Arnold Chan as Senior Vice President, Real-World Evidence Consulting

Retrieved on: 
Wednesday, June 7, 2023
Real-World Evidence, IEG, Private sector, Pharmacoepidemiology, NTU, Senior, National Taiwan University, Insight, International Society of Sculptors, Painters and Gravers, University, Research, Harvard T.H. Chan School of Public Health, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Public health, Faculty, National Perinatal Epidemiology Unit, Optum, Epidemiology, Arnold, Harvard School of Dental Medicine, Medical research, Management

CAMBRIDGE, Mass., June 7, 2023 /PRNewswire/ -- TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced that Dr. K. Arnold Chan joined the company as Senior Vice President, Real-World Evidence Consulting.

Key Points: 
  • CAMBRIDGE, Mass., June 7, 2023 /PRNewswire/ -- TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced that Dr. K. Arnold Chan joined the company as Senior Vice President, Real-World Evidence Consulting.
  • "Arnold brings over 30 years of global research experience across academia and the private sector to the TriNetX Insights and Evidence Generation (IEG) team ," said Jeffrey Brown, Chief Scientific Officer, TriNetX.
  • "We are thrilled to have him lead and grow the IEG team to support our customers' research needs."
  • "I am pleased to be a part of the Insights and Evidence Generation team at TriNetX," said Dr. Chan.

NeuroTrauma Sciences Announces Key Appointments to its Executive Leadership Team

Retrieved on: 
Wednesday, May 10, 2023
Harvard School of Dental Medicine, PPD, KU Leuven, Research and development, NTS, Medical Affairs Bureau, Pfizer, Senior, University of Brussels, Traumatic brain injury, Université Laval, Stroke, New product development, MBA, Thermo Fisher Scientific, CMO, Concordia University, Harvard T.H. Chan School of Public Health, CNS, DSM-IV codes, Bachelor of Science, Central nervous system, Eisai, Public health, Doctor of Science, MD, Columbia Business School, Tropical medicine, Master of Science, Bernhard Nocht Institute for Tropical Medicine, Quality assurance, Growth, Shirin David, Merck, Regulatory affairs, Biostatistics, MPH, VC, Epidemiology, Imperial College London, Injury, Management, Pharmaceutical industry, Neuroscience

Dr. de Somer brings more than 30 years of leadership in the biopharmaceutical industry to the NTS management team in his role as Chief Medical Officer.

Key Points: 
  • Dr. de Somer brings more than 30 years of leadership in the biopharmaceutical industry to the NTS management team in his role as Chief Medical Officer.
  • He held clinical development leadership responsibilities in Europe, the UK, and the US at Sandoz/Novartis Pharmaceuticals.
  • "We are pleased to welcome these industry veterans to our leadership team," said Carl Long, Chief Executive Officer.
  • We will value their leadership and direction as we advance NTS-104 through the clinic."